Dyno Therapeutics

Dyno Therapeutics is a biotechnology company that utilizes artificial intelligence (AI) to develop novel gene therapy vectors. The company's proprietary CapsidMap™ platform leverages machine learning and quantitative in vivo experimentation to discover and optimize Adeno-Associated Virus (AAV) capsid vectors. These vectors deliver therapeutic genes to target tissues with greater efficiency, safety, and precision than current approaches. Dyno's advanced technology has the potential to expand the range of diseases treatable with gene therapy, impacting millions of patients.

Dyno Therapeutics is a rapidly growing company with a strong focus on collaboration and innovation. The company has secured partnerships with leading gene therapy developers, including Astellas, Novartis, Roche, and Sarepta, and is actively seeking new partners. Dyno is also recognized as a leading innovator in the field, receiving numerous awards and accolades, including being named Startup of the Year by Xconomy in 2020 and being included on Forbes' list of America's Best Startup Employers in 2022 and 2023. The company is dedicated to building a diverse and inclusive team of high-potential problem solvers who are passionate about transforming patient lives with cutting-edge science.

Dyno Therapeutics offers a flexible work environment with a comprehensive benefits package that includes flexible time off, unlimited sick days, and 40 hours of paid time off for volunteer work. The company also provides employees with 12 paid holidays and parental leave.

Dyno Therapeutics offers a comprehensive benefits package including health and dental insurance through BCBS, vision coverage, a Health Savings Account, life insurance and disability coverage, a 401(k) plan, and access to KGA Life Services, which includes counseling, financial and legal consultations, and referrals for a wide range of services. Employees also enjoy flexible time off, unlimited sick days, 40 hours of time off for volunteer work, 12 paid holidays, and parental leave.

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) to gene therapy. The company's mission is to accelerate the design of Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. By building a massive and detailed map of synthetic AAV capsid sequence space, Dyno Therapeutics can quickly navigate the landscape to discover enhanced gene therapy vectors with transformative potential.

Dyno Therapeutics promotes a culture that values respect, openness, and support for its employees. They encourage bold and mindful processes, believing in the power of diverse teams tackling ambitious challenges. This collaborative environment fosters professional growth through autonomy, cross-functional understanding, and thoughtful risk-taking, leading to innovation and learning. They aim to create a sustainable workplace that balances fulfilling work with time to unplug, ensuring employee well-being and long-term excellence.

Dyno Therapeutics prioritizes a culture of diversity, equity, and inclusion by empowering diverse teams of high-potential problem solvers to transform patient lives with cutting-edge science. The company fosters a culture of respect, openness, and support for all employees, regardless of background or identity, with a focus on collaboration and bold, mindful processes. This commitment to inclusivity is reflected in their efforts to recruit diverse talent, provide a comprehensive benefits package, and create a workplace where everyone feels valued and respected.